These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25480661)

  • 1. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
    Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
    Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF inhibitor therapy in HCL.
    Dietrich S; Zenz T
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
    Falini B; Martelli MP; Tiacci E
    Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removing a hair of doubt about BRAF targeting.
    Kreitman RJ
    Blood; 2015 Feb; 125(8):1199-200. PubMed ID: 25700421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutations in hairy-cell leukemia.
    Tiacci E; Trifonov V; Schiavoni G; Holmes A; Kern W; Martelli MP; Pucciarini A; Bigerna B; Pacini R; Wells VA; Sportoletti P; Pettirossi V; Mannucci R; Elliott O; Liso A; Ambrosetti A; Pulsoni A; Forconi F; Trentin L; Semenzato G; Inghirami G; Capponi M; Di Raimondo F; Patti C; Arcaini L; Musto P; Pileri S; Haferlach C; Schnittger S; Pizzolo G; Foà R; Farinelli L; Haferlach T; Pasqualucci L; Rabadan R; Falini B
    N Engl J Med; 2011 Jun; 364(24):2305-15. PubMed ID: 21663470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib/dabrafenib and trametinib.
    Rissmann R; Hessel MH; Cohen AF
    Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomics of Hairy Cell Leukemia.
    Tiacci E; Pettirossi V; Schiavoni G; Falini B
    J Clin Oncol; 2017 Mar; 35(9):1002-1010. PubMed ID: 28297625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.
    Tiacci E; Schiavoni G; Martelli MP; Boveri E; Pacini R; Tabarrini A; Zibellini S; Santi A; Pettirossi V; Fortini E; Ascani S; Arcaini L; Inghirami G; Paulli M; Falini B
    Haematologica; 2013 Apr; 98(4):635-9. PubMed ID: 23349307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF in the cross-hairs.
    Geyer MB; Abdel-Wahab O; Tallman MS
    Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hairy cell leukemia: update and current therapeutic approach.
    Salam L; Abdel-Wahab O
    Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
    Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
    Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
    Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in
    Hartman ML; Rozanski M; Osrodek M; Zalesna I; Czyz M
    Lab Invest; 2017 Feb; 97(2):217-227. PubMed ID: 28067893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.